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Background: Chronic cerebrospinal venous insufficiency (CCSVI) is
characterized by stenoses of the internal jugular veins or the azygous vein, or
both. It has been recently reported that this condition contributes to severe
dis-regulation of the physiologic mechanisms of cerebral venous outflow in
patients with multiple sclerosis (MS). Endovascular treatment (EVT) was
demonstrated to be a safe and effective CCSVI treatment, but only in an
unblinded clinical evaluation.
Methods: We designed an open-label, magnetic resonance imaging
(MRI)-blinded, two-center, randomized, EVT intervention parallel-group,
12-month study (EVTMS) after an initial cross-sectional (CVIMS) study.
CIVMS enrolled 16 relapsing-remitting MS patients (8 from Ferrara, Italy
and 8 from Buffalo, NY). All 16 patients who completed the CVIMS study
and presented severe Doppler venous hemodynamic (VH) anomalies ac-
cepted participation in the EVT intervention prospective study (EVTMS).
Half of the cohort, the early intervention group (4 from Buffalo and 4 from
Italy), was randomly selected to have the EVT procedure in Italy at 3
months, whereas 6 patients comprised the delayed control intervention
group (late group) at 6 months; 2 patients were followed-up without any
EVT. The EVT procedure consists of selective venography complemented
by balloon dilatation when significant stenoses are detected. All patients will
be prospectively evaluated at 3, 6, 9, and 12 months with ultrasound
imaging, MRI, and clinical examinations.
Results: For the CVIMS cross-sectional study, mean age at baseline
was 36.1 7.3 years, mean disease duration was 7.51.9 years, andmedian
Expanded Disability Status Scale (EDSS) was 2.5. The mean number of
gadolinium-active lesions at baseline was 0.38  1.5. The mean number of
T2 lesions was 27.1  10.5. Median of VH of CCSVI was 4 (range, 2-5).
The six MS patients investigated and none of the HCs met the VH criteria
for CCSVI (P  .0001). MS patients showed significantly lower net cere-
brospinal fluid flow compared with the HC (P  0.038), which was
associated with the number of anomalous VH criteria present (r 0.79, P
.001; Fig, A) and confirmed by the strong relationship with the venous
hemodynamic insufficiency severity score (r 0.77, P .0007). Moreover,
increases in the number of anomalous VH criteria present were negatively
associated with lower whole brain volume (Spearman R  –0.5; P  0.05;
Fig B). The 1-year blinded EVTMS longitudinal study will be concluded
next October and results analysis completed within the Fall.
Conclusions: CCSVI is associated with abnormal cerebrospinal fluid
flow dynamics and decreased brain volume. Finally, the EVTMS study
should provide valuable data on preliminary efficacy of EVT for CCSVI
associated with MS.
Stenting of Chronically Obstructed Inferior Vena Cava Filters
P. Negle´n, M. D. Oglesbee, and S. Raju, Flowood, Miss
From River Oaks Hospital.
Background: Patients with post-thrombotic iliocaval obstruction may
have previously been protected from developing pulmonary embolism by
insertion of an inferior vena cava (IVC) filter. The aim was to study the
stent-related outcome in patients stented across an obstructed IVC filter.
Methods: From 1999 to 2009, 554 limbs underwent stenting for
post-thrombotic iliocaval outflow obstruction, including recanalization of
occlusion in 86 limbs. An IVC filter had previously been inserted in 53
patients (10%). In 25 patients, the IVC filter was obstructed (group X). The
site was traversed by a guidewire and simply balloon-dilated up to 16-atm
pressure. The filter was displaced sideways or remodeled depending on the
type of filter, including those with prongs. An appropriately sized stent was
then placed across the IVC filter and redilated. In 28 other patients, the
cephalad termination of stenting terminated below a patent IVC filter
(group B). The patients were regularly monitored with ascending or trans-
femoral venography and duplex ultrasound scanning to assess patency. The
types of reintervention were noted.
Results: The stenting maneuver through the previously inserted IVC
filter (Greenfield, 11; Recovery G2, 6; Meditech, 3; VenaTech, 2; Bird’s
Nest, 1; TrapEase, 1; Gunther Tulip, 1) was safely performed without tears
of the IVC and no subsequent bleeding. The mortality was nil, and morbid-
ity was minimal. Postoperative deep venous thrombosis 30 days occurred
in 3 of 25 (12%). The stented post-thrombotic obstruction was occlusive
requiring guidewire recanalization before stenting in 17 of 25 limbs (68%)
and in 7 of 28 limbs (25%) in group X and group B, respectively. The
cumulative secondary patency in group X (6 stents occluded, 3 reopened;
and 9 reinterventions performed in nonoccluded stents) and group B (4
stents occluded, 2 reopened; 8 reinterventions performed on nonoccluded
stents) was at 4 years, 73% and 83%, respectively (log-rank test P  .125).
The cumulative secondary patency rate of post-thrombotic limbs without a
filter (n  501) was 89% at 4 years vs 76% in those with an IVC filter (P 
.034). However, there was no difference when a comparison was made
between limbs stented for recanalized occlusion with IVC filters (n  24,
68%) and without IVC filters (n  86; 69%; P  .764).
Conclusions: Stenting across an obstructed IVC filter is safe and has
minimal morbidity whether or not the obstruction is occlusive or nonocclusive.
The patency rates are not influenced by the fact that an IVC filter is crossed by
a stent but are related to the severity of post-thrombotic disease (occlusive or
nonocclusive obstruction) and the associated recanalization procedure.
Prospective Randomized Study Comparing the Clinical Outcomes
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From Maimonides Medical Center.
Background: Although anticoagulation remains the mainstay of treat-
ment for deep venous thrombosis (DVT), the utilization of vena cava
interruption devices in patients in whom treatment has failed or in whom
anticoagulation is contraindicated remains safe and effective. In this regards,
Greenfield and TrapEase filters are arguably the most popular filtration
devices among the ones that are currently in use. The Greenfield filter, which
is available in a 12F to 14F introducer, has been in use for30 years and has
been well studied. The TrapEase filter, which is only 6F, has been available
for fewer years, with limited number of studies. Despite the popularity of
these filtration devices, there are no good guidelines in place to help
determine which filter to use in any given situation. Therefore, in this study
we prospectively compared the clinical outcomes between the above-men-
tioned filters in a randomized fashion.
Method: Between July 2006 and November 2008, 156 patients (63
men, 93 women), with a mean age of 75  13 (SD) years (range, 38-101
years) were randomized to either Greenfield (n 84) or TrapEase (n 72)
IVC filters. During this same period, 349 patients (143 men, 206 women),
who were a mean age of 75  15 years (range 24-96 years), were not
randomized. Other demographics were 26.9% malignancy and 17.3% pul-
monary embolism (PE) in the randomized group vs 16.9% malignancy and
17.2% PE in the nonrandomized group. The inclusion criteria were high-risk
procedure for thromboembolism, contraindication to anticoagulation,
failed anticoagulation, and PE. All 156 filters were inserted in the infrarenal
position by one group of surgeons at one institution using angiographic
guidance. Follow-up consisted of serial lower extremity and iliac/IVC
duplex imaging (78.2%) at postoperative day 1, the first week, every 3
months for the first year, and every 6 months for the second year, as well as
clinical evaluation and clinic visits.
Results: Indications for filter placement in the randomized group were
gastrointestinal bleeding in 37, intracranial hemorrhage in 12, free-floating clot
in 19, failure of anticoagulation in 29, PE in 27, prophylactic in 4, and others in
32. Indications for the nonrandomized group were gastrointestinal bleeding in
78, intracranial hemorrhage in 26, free-floating clot in 31, failure of anticoag-
ulation in 51, PE in 60, prophylactic in 31, and others in 77. During a mean
follow-up of 10  9 months (range, 0-33 months), symptomatic IVC/iliac
thrombosis developed in five patients (6.94%) in the TrapEase group but in
none in the Greenfield group (P  .019). Overall mortality was 32.7% (51
patients), and 30-day mortality was 13.5% (21 patients: 10 in TrapEase and 11
inGreenfield group).The studywas initially designed to recruit 360patients but
was prematurely concluded due the results.
Conclusion: There is a higher rate of symptomatic IVC filter throm-
bosis associated with TrapEase filter placement.
Fig. A, Net cerebrospinal fluid (CSF) flow was lower in patients
with multiple sclerosis and was associated with the number of
venous hemodynamic (VH) criteria present. B, Increases in the
number of anomalous VH criteria present were negatively associ-
ated with lower normalized brain volume.
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